What happened
Keith McCullough (@KeithMcCullough) posted on X on October 9, 2026. Four days earlier, two GRAIL insiders sold shares, cutting against his line. Andrew John Partridge sold 7,873 GRAL shares at $146.39 each, and Aaron Freidin sold 23,619 shares at $146.39 each.
Partridge is GRAIL's Chief Growth Officer, and his open-market sale totaled about $1.15 million in a Form 4 filed with the SEC. The filing does not mark the sale as made under a Rule 10b5-1 trading plan set up in advance. Freidin is GRAIL's Chief Financial Officer, and his open-market sale totaled about $3.46 million in a Form 4 filed with the SEC.
Read more: GRAIL (GRAL) stock analysis and investment case
Why it matters
The sales cut against the post because they were open-market sales filed four days earlier, and neither Form 4 marks a Rule 10b5-1 plan. GRAIL closed at $140.58 on October 9, 2026, 88% of the way from its 52-week low of $43.03 to its high of $154.08.
The sharper point on the other side is that a Form 4 gives no reason for an insider sale. The company case still rests on Galleri becoming the regulated, reimbursed standard for multi-cancer early detection, while 2025 revenue was $147.17 million, net margin was -277.5%, and revenue grew 17.2% on the year before.
OptimistFi's engine flagged the October 5, 2026 filing because 3 insiders sold $11.23 million within 30 days. Across 8,204 past cases at 1,754 companies, the median stock beat comparable companies by 0.6 percentage points over the next six months. That history is a record of past cases, not a forecast.
Related: Dividendology Explains Hess Midstream LP (NYSE: HESM)'s EBITDA Reset
What's next
The next known event is earnings expected around October 26, 2026. If that filing round brings fresh insider trades or a new Form 4 window, the October 5 sales can be checked against it by date and size as well.
If the earnings release also updates the path for reimbursement or approval, that would further settle whether the stock's case still rests on the Galleri story for holders. Until then, the call stands against a week-old sale record, not a fresh filing.
More from OptimistFi
- GRAL stock: the GRAIL thesis, its status and the next test to watch
- Dividendology Explains VICI Properties Inc. (NYSE: VICI)'s 8% Yield
- Biotech2k Tests Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)'s FOP Upside
- Asif Suria Tests On Holding AG (NYSE: ONON)'s $1 Billion Buyback
- Stock research on every company OptimistFi covers
- Latest stock research and investment-case updates
- OptimistFi: evidence-first equity research
Sources
- @KeithMcCullough on X, October 9, 2026 — The post this story checks
- SEC Form 4, October 5, 2026 — October 5, 2026
- SEC Form 4, October 5, 2026 — October 5, 2026
- OptimistFi engine, GRAL — October 5, 2026
- GRAIL, Inc. on OptimistFi — Prices and the standing case
Read the full OptimistFi thesis on GRAIL, Inc.: https://optimistfi.com/stocks/GRAL
See what would break the GRAIL, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full GRAIL, Inc. investment case, its status and the next test to watch live on the GRAIL, Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
